Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
$0.00
-97.7%
$0.02
$0.00
$0.45
$3K4.92615 shs279 shs
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
$0.00
$0.00
$0.00
$3.55
$1K3516.091,782 shs1,276 shs
Histogen Inc. stock logo
HSTO
Histogen
$0.00
$0.02
$0.05
$0.55
$4K1.1910,369 shsN/A
ONCSQ
OncoSec Medical
$0.00
$0.00
$0.00
$1K-19.7204 shsN/A
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00%0.00%-12.90%+28.57%-97.92%
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
0.00%0.00%0.00%+300.00%-99.99%
Histogen Inc. stock logo
HSTO
Histogen
0.00%-9.09%-96.78%-99.47%-99.69%
ONCSQ
OncoSec Medical
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.2143 of 5 stars
0.03.00.00.00.60.00.6
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
N/AN/AN/AN/AN/AN/AN/AN/A
Histogen Inc. stock logo
HSTO
Histogen
N/AN/AN/AN/AN/AN/AN/AN/A
ONCSQ
OncoSec Medical
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00
N/AN/AN/A
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
0.00
N/AN/AN/A
Histogen Inc. stock logo
HSTO
Histogen
0.00
N/AN/AN/A
ONCSQ
OncoSec Medical
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/AN/A$4.04 per shareN/A
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
$17.42M0.00N/AN/A$14.02 per share0.00
Histogen Inc. stock logo
HSTO
Histogen
$19K0.22N/AN/A$3.13 per share0.00
ONCSQ
OncoSec Medical
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
-$8.63M-$11.01N/AN/AN/AN/AN/AN/A
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
-$17.90M-$11.31N/AN/AN/AN/AN/AN/A
Histogen Inc. stock logo
HSTO
Histogen
-$10.62M-$2.81N/AN/AN/AN/AN/AN/A
ONCSQ
OncoSec Medical
-$34.18MN/A0.00N/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/AN/AN/A
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
N/AN/AN/AN/AN/A
Histogen Inc. stock logo
HSTO
Histogen
N/AN/AN/AN/AN/A
ONCSQ
OncoSec Medical
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
5.73%
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
6.92%
Histogen Inc. stock logo
HSTO
Histogen
N/A
ONCSQ
OncoSec Medical
N/A

Insider Ownership

CompanyInsider Ownership
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
3.30%
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
8.20%
Histogen Inc. stock logo
HSTO
Histogen
3.30%
ONCSQ
OncoSec Medical
1.32%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
201.14 million1.10 millionNo Data
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
5601.76 million1.61 millionNo Data
Histogen Inc. stock logo
HSTO
Histogen
204.27 millionN/ANot Optionable
ONCSQ
OncoSec Medical
405.96 million5.88 millionNot Optionable

Recent News About These Companies

OncoSec Medical Incorporated (ONCSQ)
Clinical decision-making insights for haem/oncs
OncoSec Medical Inc ONCSQ
ONCSQ OncoSec Medical Incorporated
ONMA.BE - OncoSec Medical Inc
OncoSec Medical Inc (ONCSQ)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ampio Pharmaceuticals stock logo

Ampio Pharmaceuticals NYSE:AMPE

$0.0027 -0.11 (-97.67%)
As of 06/18/2025 12:28 PM Eastern

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.

Clever Leaves stock logo

Clever Leaves NASDAQ:CLVR

$0.0004 0.00 (0.00%)
As of 06/18/2025 11:41 AM Eastern

Clever Leaves Holdings Inc. operates in the botanical cannabinoid and nutraceutical industries. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment cultivates, extracts, manufactures, commercializes, and distributes cannabinoid products comprising cannabis flowers, cannabidiol isolates, full spectrum and standardized extracts, and dry smokable flowers internationally. The Non-Cannabinoid segment formulates, manufactures, markets, sells, distributes, and commercializes nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. It also produces extracted products, including isolates, crude oil extracts, and oral solutions; and tetrahydrocannabinol flowers. The company serves retail distributors, pharmaceutical and cannabis companies, and pharmacies. Clever Leaves Holdings Inc. was founded in 2017 and is based in Tocancipá, Colombia.

Histogen stock logo

Histogen NASDAQ:HSTO

$0.0010 0.00 (0.00%)
As of 06/17/2025

Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of various inflammatory diseases. Histogen Inc. was founded in 2007 and is based in San Diego, California. On April 18, 2024, Histogen Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of California.

OncoSec Medical NASDAQ:ONCSQ

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey. On June 14, 2023, OncoSec Medical Incorporated filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of New Jersey.